Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)

14 november 2026 uppdaterad av: Jing Ma

Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.

This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
  2. Adults aged 18 to 65 years;
  3. ECV greater than 30%;
  4. No participation in other clinical trials within the past three months.

Exclusion Criteria:

  1. Diagnosed with diabetes mellitus or prediabetes;
  2. History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
  3. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
  4. Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
  5. Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
  6. Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
  7. Concurrent malignant tumors;
  8. Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
  9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
  10. Cognitive impairment, or concomitant infectious or autoimmune diseases;
  11. History of recurrent urinary or reproductive tract infections;
  12. Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
  13. Pregnant or breastfeeding women.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Interventionsgrupp

Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment.

Aktiv komparator: Control Group

oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day).

Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Tidsram: Baseline to Week 24

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Baseline to Week 24

Sekundära resultatmått

Resultatmått
Tidsram
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Output at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Heart Rate at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Peak Filling Rate at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Index at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Weight at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Total Cholesterol at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Triglycerides at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Tidsram: Baseline to Week 24
Baseline to Week 24

Andra resultatmått

Resultatmått
Tidsram
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tidsram: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Genitourinary Tract Infections
Tidsram: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Gastrointestinal Adverse Events
Tidsram: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Ketoacidosis
Tidsram: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Serious Adverse Events (SAEs)
Tidsram: Up to 48 Weeks
Up to 48 Weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 oktober 2028

Avslutad studie (Beräknad)

1 oktober 2028

Studieregistreringsdatum

Först inskickad

1 november 2026

Först inskickad som uppfyllde QC-kriterierna

14 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • LY2026-317-C

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .